Clinical trial Archives

News and Trends 7 Nov 2022

Proteins identified by FunSel and developed by Forcefield can preserve heart function

Forcefield Therapeutics, has presented positive preclinical data on three proteins identified by it FunSel platform that have the potential to preserve heart function following a heart attack. The company that works with therapeutics to protect heart function by arresting the loss of cardiomyocytes following myocardial infarction infarction. The paper, Novel Recombinant Cardioprotective Factors Against Myocardial […]

November 7, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Nov 2022

Ascentage Pharma gives positive news on chronic hepatitis B drug

Ascentage Pharma has released results from a phase I study of the investigational inhibitor of apoptosis protein (IAP) antagonist APG-1387 in Chinese patients with chronic hepatitis B (CHB). The results were presented at the 73rd American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022). This is the world’s first clinical study reporting […]

November 7, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Nov 2022

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […]

November 4, 2022 - 4 minutesmins - By Liza Laws

More News! 4 Nov 2022

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

A drug being developed jointly by Sanofi and AstraZeneca for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants was approved today (November 4). The European Commission has approved Beyfortus which is so far the first and only broadly protective option against the virus. Thomas Triomphe, executive vice president, […]

November 4, 2022 - 2 minutesmins - By Liza Laws

News and Trends 4 Nov 2022

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA). This will enable the company to start initiating a clinical trial for type 1 diabetes using AlloStem. The primary objective of the study is to evaluate Allostem in patients with […]

November 4, 2022 - 3 minutesmins - By Liza Laws

More News! 4 Nov 2022

Alimentiv and Summit collaborate to tackle liver disease NASH

Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit Clinical Research, in a bid to tackle non-alcoholic steatohepatitis (NASH). They announced a strategic alliance to tackle the now growing global epidemic with no approved treatments. It says that current challenges include optimizing and end-point assessment, minimizing screen failures and […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Trial and new drug for Tourette Syndrome after $250M after funding round completed

A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […]

November 3, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […]

November 3, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […]

November 2, 2022 - 3 minutesmins - By Liza Laws

News and Trends 2 Nov 2022

CV6 Therapeutics raises $9.2M to test cancer drug

CV6 Therapeutics has secured $9.2m to progress its lead oncology asset, CV6-168, into a first-in-human phase 1a clinical trial and perform further scientific development work. CV6 Therapeutics is a drug development biotechnology company specializing in innovative small molecule therapeutics for cancer and inflammatory diseases. Investors participating in the financing include QUBIS, the commercialization arm of […]

November 2, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 2 Nov 2022

AELIX Therapeutics publishes positive data on its HIV vaccine

Positive results from a clinical study into biotech company, AELIX’ Therapeutics’, HIV vaccine have been published in Nature Medicine journal. The announcement came today (November 2) from the Spanish-based company that specializes in developing immunotherapies for HIV infection. Christian Brander, co-founder and chief scientific officer at AELIX, said: “We are excited to have published the […]

November 2, 2022 - 3 minutesmins - By Liza Laws

More News! 31 Oct 2022

New drug application for chronic kidney disease sparks $35M milestone payment

A submission has been made for a new drug application by Japanese Kyowa Kirin Co. Ltd. for the improvement of hyperphosphatemia in patients with chronic kidney disease (CKD). The company has submitted the application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for tenapanor, which helps those with CKD on dialysis. Ardelyx, Inc. […]

October 31, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clinical trial

Proteins identified by FunSel and developed by Forcefield can preserve heart function

Ascentage Pharma gives positive news on chronic hepatitis B drug

EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease

Sanofi and AstraZeneca drug, Beyfortus, for RSV in babies and children approved

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Alimentiv and Summit collaborate to tackle liver disease NASH

Trial and new drug for Tourette Syndrome after $250M after funding round completed

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Authorization given to BeiGene’s chemo-free treatment option for lymphoma

CV6 Therapeutics raises $9.2M to test cancer drug

AELIX Therapeutics publishes positive data on its HIV vaccine

New drug application for chronic kidney disease sparks $35M milestone payment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!